Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells

Shimada,Takehiro; Tsuruta,Masashi; Hasegawa,Hirotoshi; Okabayashi,Koji; Shigeta,Kohei; Ishida,Takashi; Asada,Yusuke; Suzumura,Hirofumi; Koishikawa,Kaoru; Akimoto,Shingo; Kitagawa,Yuko

doi:10.3892/or.2018.6180

Heat shock protein 27 knockdown using nucleotide‑based therapies enhances sensitivity to 5-FU chemotherapy in SW480 human colon cancer cells

Authors:
- Takehiro Shimada
- Masashi Tsuruta
- Hirotoshi Hasegawa
- Koji Okabayashi
- Kohei Shigeta
- Takashi Ishida
- Yusuke Asada
- Hirofumi Suzumura
- Kaoru Koishikawa
- Shingo Akimoto
- Yuko Kitagawa
View Affiliations

Affiliations: Department of Surgery, Keio University School of Medicine, Tokyo 160-8582, Japan
Published online on: January 3, 2018 https://doi.org/10.3892/or.2018.6180
Pages: 1119-1124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock protein 27 (Hsp27) is a chaperone protein of low molecular weight that is produced in response to various stresses and has a cytoprotective function. In the present study we found that there is a strong correlation between sensitivity to 5-fluorouracil (5-FU) and the expression of Hsp27 in colorectal cancer. Apatorsen is an antisense oligonucleotide that targets Hsp27 and has various antitumor effects in some types of cancer, such as bladder and prostate. Although several clinical studies are currently studying apatorsen in many malignancies, to date no promising results have been reported for colorectal cancer. In the present study, we examined the impact of Hsp27 downregulation (via apatorsen) on 5-FU sensitivity in colon cancer both in vitro and in vivo. In vitro, apatorsen significantly decreased the levels of Hsp27 in a dose-dependent manner in human colon cancer SW480 cells. A cell proliferation assay revealed that although apatorsen did not inhibit tumor growth, it resulted in greater 5-FU sensitivity in comparison with treatment with OGX-411 (control). In vivo, intraperitoneal injection of apatorsen decreased the levels of Hsp27 in subcutaneous tumors in a xenograft mouse model using SW480 cells and enhanced 5-FU sensitivity, compared to controls. Although further research is warranted, the present study confirmed that concurrent treatment with Hsp27 knockdown using apatorsen and 5-FU could be a promising therapy for colon cancer.

View Figures

View References

1	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
2	Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: Updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
4	Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, et al: FIRE-3 investigators: FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): A post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 17:1426–1434. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ciocca DR and Calderwood SK: Heat shock proteins in cancer: Diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 10:86–103. 2005. View Article : Google Scholar : PubMed/NCBI
6	Paul C, Simon S, Gibert B, Virot S, Manero F and Arrigo AP: Dynamic processes that reflect anti-apoptotic strategies set up by HspB1 (Hsp27). Exp Cell Res. 316:1535–1552. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y and Foster CS: Heat shock protein expression independently predicts clinical outcome in prostate cancer. Cancer Res. 60:7099–7105. 2000.PubMed/NCBI
8	Love S and King RJ: A 27 kDa heat shock protein that has anomalous prognostic powers in early and advanced breast cancer. Br J Cancer. 69:743–748. 1994. View Article : Google Scholar : PubMed/NCBI
9	Langdon SP, Rabiasz GJ, Hirst GL, King RJ, Hawkins RA, Smyth JF and Miller WR: Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res. 1:1603–1609. 1995.PubMed/NCBI
10	Tsuruta M, Nishibori H, Hasegawa H, Ishii Y, Endo T, Kubota T, Kitajima M and Kitagawa Y: Heat shock protein 27, a novel regulator of 5-fluorouracil resistance in colon cancer. Oncol Rep. 20:1165–1172. 2008.PubMed/NCBI
11	Hayashi R, Ishii Y, Ochiai H, Matsunaga A, Endo T, Hasegawa H and Kitagawa Y: Suppression of heat shock protein 27 expression promotes 5-fluorouracil sensitivity in colon cancer cells in a xenograft model. Oncol Rep. 28:1269–1274. 2012. View Article : Google Scholar : PubMed/NCBI
12	Rocchi P, So A, Kojima S, Signaevsky M, Beraldi E, Fazli L, Hurtado-Coll A, Yamanaka K and Gleave M: Heat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancer. Cancer Res. 64:6595–6602. 2004. View Article : Google Scholar : PubMed/NCBI
13	Zellweger T, Miyake H, July LV, Akbari M, Kiyama S and Gleave ME: Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia. 3:360–367. 2001. View Article : Google Scholar : PubMed/NCBI
14	Kamada M, So A, Muramaki M, Rocchi P, Beraldi E and Gleave M: Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther. 6:299–308. 2007. View Article : Google Scholar : PubMed/NCBI
15	Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, et al: OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2:e2212011. View Article : Google Scholar : PubMed/NCBI
16	Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, Higano CS, Mukherjee SD, Gleave ME, Stewart PS and Hotte SJ: A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann Oncol. 27:1116–1122. 2016. View Article : Google Scholar : PubMed/NCBI
17	Yamamoto K, Okamoto A, Isonishi S, Ochiai K and Ohtake Y: Heat shock protein 27 was up-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance. Cancer Lett. 168:173–181. 2001. View Article : Google Scholar : PubMed/NCBI
18	Yamauchi T, Watanabe M, Hasegawa H, Nishibori H, Ishii Y, Tatematsu H, Yamamoto K, Kubota T and Kitajima M: The potential for a selective cyclooxygenase-2 inhibitor in the prevention of liver metastasis in human colorectal cancer. Anticancer Res. 23(1A): 1–249. 2003.PubMed/NCBI
19	Kadota Y, Yagi H, Inomata K, Matsubara K, Hibi T, Abe Y, Kitago M, Shinoda M, Obara H, Itano O, et al: Mesenchymal stem cells support hepatocyte function in engineered liver grafts. Organogenesis. 10:268–277. 2014. View Article : Google Scholar : PubMed/NCBI
20	Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, Albuquerque RJ, Yamasaki S, Itaya M, Pan Y, et al: Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 452:591–597. 2008. View Article : Google Scholar : PubMed/NCBI
21	Asami Y, Yoshioka K, Nishina K, Nagata T and Yokota T: Drug delivery system of therapeutic oligonucleotides. Drug Discov Ther. 10:256–262. 2016. View Article : Google Scholar : PubMed/NCBI
22	Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C and Gleave M: Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res. 67:10455–10465. 2007. View Article : Google Scholar : PubMed/NCBI
23	Shiota M, Bishop JL, Nip KM, Zardan A, Takeuchi A, Cordonnier T, Beraldi E, Bazov J, Fazli L, Chi K, et al: Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Res. 73:3109–3119. 2013. View Article : Google Scholar : PubMed/NCBI
24	Rocchi P, Beraldi E, Ettinger S, Fazli L, Vessella RL, Nelson C and Gleave M: Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. Cancer Res. 65:11083–11093. 2005. View Article : Google Scholar : PubMed/NCBI
25	Concannon CG, Orrenius S and Samali A: Hsp27 inhibits cytochrome c-mediated caspase activation by sequestering both pro-caspase-3 and cytochrome c. Gene Expr. 9:195–201. 2001. View Article : Google Scholar : PubMed/NCBI
26	Garrido C, Ottavi P, Fromentin A, Hammann A, Arrigo AP, Chauffert B and Mehlen P: HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs. Cancer Res. 57:2661–2667. 1997.PubMed/NCBI
27	Rogalla T, Ehrnsperger M, Preville X, Kotlyarov A, Lutsch G, Ducasse C, Paul C, Wieske M, Arrigo AP, Buchner J, et al: Regulation of Hsp27 oligomerization, chaperone function, and protective activity against oxidative stress/tumor necrosis factor alpha by phosphorylation. J Biol Chem. 274:18947–18956. 1999. View Article : Google Scholar : PubMed/NCBI
28	Wyttenbach A, Sauvageot O, Carmichael J, Diaz-Latoud C, Arrigo AP and Rubinsztein DC: Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. Hum Mol Genet. 11:1137–1151. 2002. View Article : Google Scholar : PubMed/NCBI
29	Garrido C, Schmitt E, Candé C, Vahsen N, Parcellier A and Kroemer G: HSP27 and HSP70: Potentially oncogenic apoptosis inhibitors. Cell Cycle. 2:579–584. 2003. View Article : Google Scholar : PubMed/NCBI
30	Kluck RM, Bossy-Wetzel E, Green DR and Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for Bcl-2 regulation of apoptosis. Science. 275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
31	Matsunaga A, Ishii Y, Tsuruta M, Okabayashi K, Hasegawa H and Kitagawa Y: Inhibition of heat shock protein 27 phosphorylation promotes sensitivity to 5-fluorouracil in colorectal cancer cells. Oncol Lett. 8:2496–2500. 2014. View Article : Google Scholar : PubMed/NCBI